Physician profile
Frederick Koehler
NPI 1134814965
$5,857.62
in general payments reported to CMS, 2019-2025
24 companies · $3,816 in 2025
The $3,816 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.69 · 2024: $1,997 · 2025: $3,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,857.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $923.32 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $826.23 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $510.00 | 2024-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $391.27 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $367.70 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $351.46 | 2024-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $287.22 | 2024-2025 | Xelstrym |
| Abbvie INC. | $276.74 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $247.40 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $230.95 | 2024-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $219.25 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $218.06 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Indivior INC. | $168.23 | 2024-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $156.95 | 2024 | |
| Bausch Health US, LLC | $121.67 | 2024-2025 | Aplenzin, Wellbutrin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $121.06 | 2024-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $117.75 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $76.07 | 2024-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $53.47 | 2024 | Jardiance, Zepbound |
| Almatica Pharma LLC | $52.06 | 2024 | Loreev Xr |
| Novo Nordisk INC | $48.27 | 2025 | Wegovy |
| Supernus Pharmaceuticals, INC. | $43.83 | 2025 | Qelbree |
| Corium, LLC | $34.11 | 2024 | Azstarys |
| Neos Therapeutics, LP | $14.55 | 2025 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Koehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.